Radiation is commonly used to kill cancer cells and shrink tumours. Stereotactic Ablative Radiosurgery (SABR) is used to treat cancers using substantially higher doses of radiation than conventional radiotherapy. This technology is able to deliver higher doses of radiation to a tumour, while limiting the dose of radiation to nearby normal tissues.
SABR is commonly employed in cancers of the lung, liver, and pancreas, where it is used to shrink tumours that have spread to other parts of the body.
The purpose of this trial is to explore the safety and effectiveness of giving five rounds of SABR to patients with advanced kidney cancer.
Patients on this trial will be followed at 4-month intervals for up to 2 years after receiving SABR. During the follow-ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.
- Any Subtype
- Advanced kidney cancer that cannot be removed by surgery
- Only tumours under 6cm in diameter are eligible for SABR
Additional eligibility criteria will apply. Please speak to your doctor.Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreRoyal Victoria Regional Health Centre||Principal Investigator||LocationBarrie, ON||Trial StatusNot Yet recruiting|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre | University Health Network||Principal InvestigatorDr Joelle Helou||LocationHamilton, ON||Trial StatusRecruiting|